News
Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...
Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...
Eli Lilly will add 12.5 mg and 15 mg single-dose vials of its weight loss drug Zepbound to its LillyDirect platform starting July 7, completing the full range of approved doses. All vial doses, ...
Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...
Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...
Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.
Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...
We examine the labor market effects of AI chatbots using two large-scale adoption ... AI chatbots have had no significant impact on earnings or recorded hours in any occupation, with confidence ...
The U.S. added 177,000 jobs, handily topping the 133,000 forecast by surveyed economists. That was down from from a revised 185,000 in March. The unemployment rate held steady at 4.2%, as expected ...
Hosted on MSN14d
Aswath Damodaran explains 3 reasons why Moody’s ratings downgrade of the U.S. didn’t impact marketWhile the downgrade has had little market impact, Damodaran said that it does carry implications for valuation and investment analysis. Specifically, analysts can no longer assume the U.S. 10-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results